iOmx Therapeutics AG

Wrapping up an insightful and productive EORTC-NCI-AACR Symposium in Barcelona! In addition to presenting key data on OMX-0407 and IOMX-0675, Ilona-Petra Maser and Kristina Heinig had valuable discussions with clinical investigators, research collaborators, and partners that are driving our projects forward. We're looking forward to keeping this momentum going as we advance our pipeline of promising drug candidates with the potential to address cancers resistant to current immunotherapies.   #CancerResearch #ImmunoOncology #Immunotherapy #ClinicalTrials #ENASymp24   EORTC - European Organisation for Research and Treatment of Cancer National Cancer Institute (NCI) American Association for Cancer Research

#BIOEurope 2024 is just around the corner, and iOmx is ready to explore new opportunities in Stockholm from November 4 - 6! Our Chief Business Officer, Nils Debus, will be on-site to discuss iOmx’s innovative oncology pipeline, including: • OMX-0407, a spectrum-selective kinase inhibitor currently in Phase Ib clinical development in selected advanced solid tumor indications • IOMX-0675, a cross-specific antibody targeting LILRB1/2, with CTA filing anticipated by end of 2024 and a first in human study in advanced solid tumors to be initiated in 2025 • A debut at BIO-Europe: IMT-40, an antibody program blocking a shared co-receptor of two immuno-suppressive cytokines on track to clinical leads nomination • iOTarg™, our proprietary target discovery platform We’re actively seeking strategic partnerships and collaborations - connect with us through the #partneringONE platform here (https://lnkd.in/dsxntjC8) or contact us at info@iomx.com.   EBD Group #BIOEurope #ImmunoOncology #Biotech #pharmapartners #drugdevelopment

It is a busy season for the iOmx team, with several scientific conferences on the agenda! Meet our colleagues Ilona-Petra Maser and Kristina Heinig at the upcoming 36th EORTC-NCI-AACR Symposium in Barcelona, Spain, October 23-25.   Key scientific posters on October 24th: Ilona-Petra, Group Leader Preclinical Pharmacology & Biomarker Development at iOmx, will focus on OMX-0407, a spectrum-selective kinase inhibitor that has shown preclinical and clinical efficacy in angiosarcoma, a malignancy with high unmet medical need.   Kristina, Group Leader Preclinical Pharmacology & Biomarker Development at iOmx will present data on IOMX-0675, a highly differentiated cross-specific antibody targeting the immunosuppressive receptors LILRB1 and LILRB2. By repolarizing myeloid cells and activating cytotoxic T cells, IOMX-0675 induces potent tumor cell killing - a promising novel approach in cancer immunotherapy.   These presentations highlight iOmx's dedication to pioneering novel therapeutic strategies, with OMX-0407 and IOMX-0675 as key candidates in our mission to shape the future of cancer therapy.   We look forward to meeting with fellow researchers and industry experts to explore these exciting developments further!   #CancerResearch #ImmunoOncology #Immunotherapy #ClinicalTrials #ENASymp24   EORTC - European Organisation for Research and Treatment of Cancer National Cancer Institute (NCI) American Association for Cancer Research

Meet our CDO Christine Rothe and Jonas Schilz, Group Leader Antibody Discovery and Protein Interactions of iOmx, at the Festival of Biologics from October 15-17, 2024, in Basel.   Join Christine’s presentation on October 16th at 14:20 CET in the Targeting Checkpoint Pathways track as she dives into the science behind IOMX-0675, our cross-specific antibody that targets LILRB1 and LILRB2. This antibody is engineered to effectively repolarize the tumor microenvironment by antagonizing these two immuno-suppressive receptors while sparing the immuno-activating family members. The result is enhanced myeloid and lymphoid cell activation, leading to potent tumor cell destruction.   Take part in shaping the future of biologics for the treatment of cancer!   #CancerResearch #Immunotherapy #ImmunoOncology #TumorMicroenvironment #Biologics #FestivalOfBiologics

We look forward to hearing Christine Rothe, CDO of iOmx, speak at the 6th Annual Macrophage-Directed Therapies Summit in Boston on October 2nd. Christine will provide key insights into IOMX-0675, our highly differentiated, fully human, cross-specific antibody targeting LILRB1 and LILRB2. In the presentation, Christine will discuss how IOMX-0675 effectively repolarizes the tumor microenvironment, resulting in potent tumor cell killing both 𝘪𝘯 𝘷𝘪𝘵𝘳𝘰 and 𝘪𝘯 𝘷𝘪𝘷𝘰. Also, Christine will highlight IOMX-0675's unique binding profile, which selectively antagonizes the immunosuppressive receptors LILRB1 and LILRB2 while sparing the immuno-activating family members. This differentiation results in superior macrophage repolarization and immune cell activation compared to other antibodies. 🔬   📢 Stay tuned for further updates!   Hanson Wade Group #CancerResearch #Macrophages #immunotherapy #ImmunoOncology

🎥 Exciting updates on OMX-0407 from #ESMO24! 🎥   We spoke to Dr. Valentina Boni, Principal Investigator at a Madrid clinical trial site for the first-in-human trial with OMX-0407. She shared her experiences of the dose escalation study, including the complete response of a patient with angiosarcoma. Dr. Boni describes the patient's journey after two lines of standard chemotherapy before the trial and how OMX-0407 led to the complete disappearance of tumor lesions.   Expansion cohorts are currently underway in Spain and Belgium to further evaluate OMX-0407 in kidney cancer and angiosarcoma.   Watch the video to learn more about OMX-0407 and stay tuned for more updates on our promising drug candidate.   ESMO - European Society for Medical Oncology Tiantom (Dom) J.   #ImmunoOncology #oncology #ClinicalResearch #ClinicalTrials

Johannes Loferer, COO, Murray Yule, CMO, and Tiantom (Dom) J. Jarutat, MD, VP of Clinical Development at iOmx are gearing up for #ESMO24 in Barcelona! 🧬 They are looking forward to meeting fellow experts and partners and will be connecting with the clinical trial investigators of the ongoing Phase I study of OMX-0407, iOmx’ first-in-class, spectrum-selective SIK inhibitor. 🥼 Recently, the OMX-0407 Phase I study has demonstrated a favorable safety profile and early signs of anti-tumor activity in its dose escalation part, including a durable complete response in a high unmet need indication. The study has now opened the dose expansion part for recruitment of patients with kidney cancer and angiosarcoma, other key solid tumor indications are planned for clinical investigation. 📅 See you in Barcelona for ESMO 2024! ESMO - European Society for Medical Oncology #ImmunoOncology #oncology #ClinicalResearch

Christina Hartl, Senior Scientist at iOmx, will present our latest research on IOMX-0675 at #CICON24 in Washington, D.C. IOMX-0675 is a highly differentiated, cross-specific antibody targeting LILRB1 and LILRB2, two key immunosuppressive receptors in the myeloid compartment. Dual targeting of these receptors results in a pronounced anti-tumor immune response, retuning the tumor microenvironment and activating T cells against cancer cells. The specificity and dual-approach of IOMX-0675 indicate its potential as a promising avenue to improve cancer treatment across a range of solid tumors. For more details, read the abstract here: page 78 https://lnkd.in/d3_Ddnhc 📅 Mark your calendar: Tuesday, September 10th ⏰ Time: 11:55 AM - 1:55 PM EDT 📍 Location: Cherry Blossom Ballroom, Poster Board 084-B We’re looking forward to discussing our work with fellow scientists interested to explore how this research could potentially shape the future of cancer immunotherapy. Do stop by and talk with us!   #immunotherapy #CancerResearch Cancer Research Institute (CRI) European Network for Cancer Immunotherapy

💊 iOmx Therapeutics initiates Phase Ib with OMX-0407 💊 Following the successful completion of the dose escalation segment of our phase Ia/Ib clinical trial, we are pleased to announce the initiation of the expansion part with OMX-0407. This is an important milestone in our mission to develop a first-in-class, spectrum-selective SIK kinase inhibitor for the treatment of advanced solid tumors.   Leading to this decision was the favorable safety profile and promising anti-tumor activity of OMX-0407 monotherapy demonstrated in the phase Ia part. Notably, one patient who was resistant to multiple previous chemotherapies achieved a durable complete response with disappearance of all tumor lesions in a high-medical-need indication. The phase Ib segment will initially focus on two priority indications – kidney cancer and angiosarcoma, amongst other prioritized solid tumor indications – and will enroll up to 86 patients. The primary endpoint is objective response rate, with secondary endpoints including duration of response and patient survival. 👉 For more details, read the full press release on our website: https://lnkd.in/dm-sFA7x #ClinicalTrials #Oncology #DrugDevelopment #Biotech #CancerResearch

We are proud to announce advancements in our colorectal cancer research through our proprietary iOTarg™ screening platform, recently presented at #AACR24. Our expert team has successfully identified novel targets that sensitize colorectal cancer to immune-mediated killing. We were able to confirm our approach by rediscovery of targets in late-stage clinical development. Our findings reveal that some of these intra- and extracellular targets not only directly affect tumor cell viability but also bolster the immune system's ability to combat cancer. This dual effect could potentially transform the treatment landscape for colorectal cancer, offering new hope for patients. The identified targets are enriched in pathways such as apoptosis resistance, DNA damage repair, cell cycle regulation and proteasome function. Stay tuned as we continue to investigate these targets and their promise for clinical therapy. If you would like to join our endeavor and collaborate on our novel CRC targets, contact us at: info@iomx.com #immunooncology #immunotherapies #colorectalcancer